<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antifungal prophylaxis in the haematological patient is currently regarded as the gold standard in situations with a high risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, such as <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemias</z:mpath>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and autologous or allogenic hematopoietic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Over the years, different scientific societies have established a series of recommendations on antifungal prophylaxis based on prospective studies performed with different drugs </plain></SENT>
<SENT sid="2" pm="."><plain>However, the prescription of each one of the agents must be personalised, adapted to the characteristics of each patient and to possible interactions with concomitant medication </plain></SENT>
</text></document>